Immuneering (IMRX) Update / Briefing June 17, 2025 08:00 AM ET Speaker0 Welcome to the Immuneering Conference Call to discuss a positive data update from the company's ongoing Phase IIa trial of atebimetinib in first line pancreatic cancer patients. At this time, all participants are in listen only mode. Following management prepared remarks, we will hold a q and a session. To ensure that we have ample time to address everyone's questions, we would ask each person to limit themselves to one question and one ...